Introgen’s NPRL2: A Novel Nanoparticle Tumor Supressor Gene Showing Promise in Reducing Tumor Growth and Reversing Resistance to Cisplatin
In some types of cancer (testicular, bladder, lung, oesophageal, stomach, ovarian) the chemotherapy drug cisplatin is one of the ever present component.
So imagine if the cancer patient develops resistance to cisplatin? No treatment effect = not getting better.
Introgen Theapeutics, Inc. (a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases), has a novel nanoparticle tumor suppressor gene tagged as NPRL2, a gene believed to be important in the genesis of multiple types of cancer.
NPRL2 is licensed to Introgen from the University of Texas M. D. Anderson Cancer Center.
From the preclinical data , Introgen announced that systemic treatment of NPRL2 nanoparticles combined with cisplatin resulted in a 90% tumor growth inhibition in human lung cancer cells compared to control treatments.
Moreover, in lung cancers that were resistant to cisplatin, re- introduction of the normal NPRL2 gene resulted in dramatic re-sensitization to cisplatin.
Find more details from Introgen’s press release.
Tags: cisplatin, Introgen-Therapeutics, NPRL2-geneRelated Stories
POSTED IN: on anti-cancer ingredients
0 opinions for Introgen’s NPRL2: A Novel Nanoparticle Tumor Supressor Gene Showing Promise in Reducing Tumor Growth and Reversing Resistance to Cisplatin
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: